MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells

PLoS ONE

Volumn 13, Issue 3, 2018, Pages

  Cong, Yu ^a   Hart, Brit J ^a,c   Gross, Robin ^a   Zhou, Huanying ^a   Frieman, Matthew ^b   Bollinger, Laura ^a   Wada, Jiro ^a   Hensley, Lisa E ^a   Jahrling, Peter B ^a   Dyall, Julie ^a   Holbrook, Michael R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; CHLOROQUINE; CHLORPROMAZINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12P40; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TOREMIFENE; TUMOR NECROSIS FACTOR; ANTIVIRUS AGENT;

ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MONOCYTE; MONOCYTE DERIVED DENDRITIC CELL; MONOCYTE DERIVED MACROPHAGE; NONHUMAN; VIRUS REPLICATION; ANIMAL; CELL CULTURE; CHLOROCEBUS AETHIOPS; CORONAVIRUS INFECTION; DRUG APPROVAL; DRUG EFFECT; IMMUNOLOGY; MACROPHAGE; PHYSIOLOGY; PRECLINICAL STUDY; TREATMENT OUTCOME; VERO CELL LINE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIVIRAL AGENTS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CORONAVIRUS INFECTIONS; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MACROPHAGES; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MONOCYTES; TREATMENT OUTCOME; VERO CELLS;

EID: 85044284357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0194868     Document Type: Article

References (46)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367(19):1814–20. Epub 2012/10/ 19. https://doi.org/10.1056/NEJMoa1211721 PMID: 23075143.
2. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. Journal of virology. 2013; 87(14):7790–2. Epub 2013/05/17. https://doi.org/10.1128/JVI.01244-13 PMID: 23678167; PubMed Central PMCID: PMCPmc3700179.
3. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)—Saudi Arabia. Disease outbreak news. Geneva, CH: World Health Organization; 2017 [cited 2017 11 September]. Available from: http://www.who.int/csr/don/6-september-2017-mers-saudi-arabia/en/.
4. Almario CV, Chey W, Kaung A, Whitman C, Fuller G, Reid M, et al. Computer-generated vs. physician-documented history of present illness (HPI): results of a blinded comparison. Am J Gastroenterol. 2015; 110(1):170–9. https://doi.org/10.1038/ajg.2014.356 PMID: 25461620; PubMed Central PMCID: PMC4289091.
5. Haagmans BL, Al Dhahiry SH, Reusken CB, Raj VS, Galiano M, Myers R, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis. 2014; 14 (2):140–5. https://doi.org/10.1016/S1473-3099(13)70690-X PMID: 24355866.
6. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). Fact sheet. Geneva, CH: World Health Organization; 2017 [updated 2017 May; cited 2017 11 September]. Available from: http://www.who.int/mediacentre/factsheets/mers-cov/en/.
7. Hui DS, Memish ZA, Zumla A. Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Current opinion in pulmonary medicine. 2014; 20(3):233–41. Epub 2014/03/15. https://doi.org/10.1097/MCP.0000000000000046 PMID: 24626235.
8. Senga M, Arabi YM, Fowler RA. Clinical spectrum of the Middle East respiratory syndrome coronavirus (MERS-CoV). J Infect Public Health. 2017; 10(2):191–4. https://doi.org/10.1016/j.jiph.2016.04.008PMID: 27140697.
9. Poissy J, Goffard A, Parmentier-Decrucq E, Favory R, Kauv M, Kipnis E, et al. Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2014; 61(2):275–8. Epub 2014/07/31. https://doi.org/10.1016/j.jcv.2014.07.002 PMID: 25073585.
10. Collins RA, Werling D, Duggan SE, Bland AP, Parsons KR, Howard CJ. Gammadelta T cells present antigen to CD4+ alphabeta T cells. Journal of leukocyte biology. 1998; 63(6):707–14. Epub 1998/06/10. PMID: 9620663.
11. Funk CJ, Wang J, Ito Y, Travanty EA, Voelker DR, Holmes KV, et al. Infection of human alveolar macrophages by human coronavirus strain 229E. The Journal of general virology. 2012; 93(Pt 3):494–503. Epub 2011/11/18. https://doi.org/10.1099/vir.0.038414-0 PMID: 22090214; PubMed Central PMCID: PMCPmc3352353.
12. Kopf M, Schneider C, Nobs SP. The development and function of lung-resident macrophages and dendritic cells. Nature immunology. 2015; 16(1):36–44. Epub 2014/12/19. https://doi.org/10.1038/ni.3052PMID: 25521683.
13. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrobial agents and chemotherapy. 2014; 58(8):4885–93. Epub 2014/05/21. https://doi.org/10.1128/AAC.03036-14 PMID: 24841273; PubMed Central PMCID: PMCPmc4136000.
14. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial agents and chemotherapy. 2014; 58(8):4875–84. https://doi.org/10.1128/AAC.03011-14 PMID: 24841269; PubMed Central PMCID: PMC4136071.
15. Cong Y, McArthur MA, Cohen M, Jahrling PB, Janosko KB, Josleyn N, et al. Characterization of yellow fever virus infection of human and non-human primate antigen presenting cells and their Interaction with CD4+ T Cells. PLoS Negl Trop Dis. 2016; 10(5):e0004709. https://doi.org/10.1371/journal.pntd. 0004709 PMID: 27191161; PubMed Central PMCID: PMC4871483.
16. Sandow D, Hofmann F, Gropler K, Nuhn P. [Statistical analysis of the in-vitro action of combination antiviral agents]. Z Gesamte Hyg. 1990; 36(9):471–4. PMID: 2173288.
17. Wulff NH, Tzatzaris M, Young PJ. Monte Carlo simulation of the Spearman-Kaerber TCID50. J Clin Bioinforma. 2012; 2(1):5. https://doi.org/10.1186/2043-9113-2-5 PMID: 22330733; PubMed Central PMCID: PMC3331834.
18. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nature reviews Microbiology. 2013; 11(12):836–48. Epub 2013/11/13. https://doi.org/10.1038/ nrmicro3143 PMID: 24217413.
19. Chu H, Zhou J, Wong BH, Li C, Cheng ZS, Lin X, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology. 2014; 454–455:197–205. https://doi.org/10.1016/j.virol.2014.02.018 PMID: 24725946.
20. Fugier-Vivier I, Servet-Delprat C, Rivailler P, Rissoan MC, Liu YJ, Rabourdin-Combe C. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med. 1997; 186(6):813–23. PMID: 9294136; PubMed Central PMCID: PMC2199042.
21. Granelli-Piperno A, Finkel V, Delgado E, Steinman RM. Virus replication begins in dendritic cells during the transmission of HIV-1 from mature dendritic cells to T cells. Curr Biol. 1999; 9(1):21–9. PMID: 9889121.
22. Rescigno M, Winzler C, Delia D, Mutini C, Lutz M, Ricciardi-Castagnoli P. Dendritic cell maturation is required for initiation of the immune response. Journal of leukocyte biology. 1997; 61(4):415–21. PMID: 9103227.
23. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18:767–811. https://doi.org/10.1146/annurev.immunol.18.1.767 PMID: 10837075.
24. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997; 90(9):3245–87. PMID: 9345009.
25. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregu-lated by tumor necrosis factor alpha. J Exp Med. 1994; 179(4):1109–18. PMID: 8145033; PubMed Central PMCID: PMC2191432.
26. Spiegel M, Schneider K, Weber F, Weidmann M, Hufert FT. Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. The Journal of general virology. 2006; 87(Pt 7):1953–60. Epub 2006/06/09. https://doi.org/10.1099/vir.0.81624-0 PMID: 16760397.
27. Kruse M, Rosorius O, Kratzer F, Stelz G, Kuhnt C, Schuler G, et al. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. Journal of virology. 2000; 74 (15):7127–36. PMID: 10888653; PubMed Central PMCID: PMC112231.
28. Alloatti A, Kotsias F, Magalhaes JG, Amigorena S. Dendritic cell maturation and cross-presentation: timing matters! Immunol Rev. 2016; 272(1):97–108. https://doi.org/10.1111/imr.12432 PMID: 27319345.
29. Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, et al. Clinical features and viro-logical analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 2013; 13(9):745–51. Epub 2013/06/21. https://doi.org/10.1016/S1473-3099(13)70154-3 PMID: 23782859.
30. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, et al. An interferon-gamma-related cytokine storm in SARS patients. Journal of medical virology. 2005; 75(2):185–94. Epub 2004/12/17. https://doi.org/10.1002/jmv.20255 PMID: 15602737.
31. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003; 361(9371):1773–8. PMID: 12781536.
32. Zhou J, Chu H, Li C, Wong BH, Cheng ZS, Poon VK, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. The Journal of infectious diseases. 2014; 209(9):1331–42. Epub 2013/09/26. https://doi.org/10.1093/infdis/jit504 PMID: 24065148.
33. Jiang Y, Xu J, Zhou C, Wu Z, Zhong S, Liu J, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. American journal of respiratory and critical care medicine. 2005; 171(8):850–7. Epub 2005/01/20. https://doi.org/10.1164/rccm.200407-857OC PMID: 15657466.
34. Tynell J, Westenius V, Ronkko E, Munster VJ, Melen K, Osterlund P, et al. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. The Journal of general virology. 2016; 97(2):344–55. https://doi.org/10.1099/jgv.0.000351 PMID: 26602089; PubMed Central PMCID: PMC4804640.
35. Scheuplein VA, Seifried J, Malczyk AH, Miller L, Hocker L, Vergara-Alert J, et al. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. Journal of virology. 2015; 89(7):3859–69. https://doi.org/10.1128/JVI.03607-14 PMID: 25609809; PubMed Central PMCID: PMC4403407.
36. Bergamaschi A, Pancino G. Host hindrance to HIV-1 replication in monocytes and macrophages. Retro-virology. 2010; 7:31. https://doi.org/10.1186/1742-4690-7-31 PMID: 20374633; PubMed Central PMCID: PMC2868797.
37. Josset L, Menachery VD, Gralinski LE, Agnihothram S, Sova P, Carter VS, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio. 2013; 4(3):e00165–13. https://doi.org/10.1128/mBio.00165-13 PMID: 23631916; PubMed Central PMCID: PMC3663187.
38. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013; 5(190):190ra79. https://doi.org/10.1126/scitranslmed.3005471 PMID: 23785035; PubMed Central PMCID: PMC3955358.
39. Thome R, Moraes AS, Bombeiro AL, Farias Ados S, Francelin C, da Costa TA, et al. Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis. PLoS One. 2013; 8(6):e65913. https://doi.org/10.1371/journal.pone.0065913 PMID: 23799062; PubMed Central PMCID: PMC3683039.
40. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003; 3(11):722–7. PMID: 14592603.
41. Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct. 2016; 34 (4):191–6. https://doi.org/10.1002/cbf.3182 PMID: 27001679; PubMed Central PMCID: PMC5071688.
42. Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res. 2015; 4:30. https://doi.org/10.12688/f1000research.6085.2 PMID: 26069727; PubMed Central PMCID: PMC4431382.
43. Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013; 8(4):e60579. https://doi.org/10.1371/journal.pone.0060579 PMID: 23577127; PubMed Central PMCID: PMC3618516.
44. Porotto M, Orefice G, Yokoyama CC, Mungall BA, Realubit R, Sganga ML, et al. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. Journal of virology. 2009; 83(10):5148–55. https://doi.org/10.1128/JVI.00164-09 PMID: 19264786; PubMed Central PMCID: PMC2682105.
45. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012; 17(12):1206–27. https://doi.org/10.1038/mp.2012.47 PMID: 22584864.
46. Chu JJ, Ng ML. Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. Journal of virology. 2004; 78(19):10543–55. https://doi.org/10.1128/JVI.78.19.10543-10555.2004PMID: 15367621; PubMed Central PMCID: PMC516396.